Supporting the validation of the new allergic and hypersensitivity conditions section of the World Health Organization International Classification of Diseases-11

BACKGROUND: The new International Classification of Diseases (ICD)-11 "Allergic and hypersensitivity conditions" section has been constructed as a result of a detailed and careful action plan based on scientific evidences for the necessity of changes and collaboration with the World Health Organization (WHO) ICD-11 revision governance. All the efforts are being acknowledged by the Joint Allergy Academies. OBJECTIVE: Considering the new classification model addressed to the allergic and hypersensitivity conditions and following the ICD WHO agenda, we believe it is the appropriate time to start supporting the validation process in collaboration with the WHO ICD governance. METHODS: We conducted a mapping of ICD-10 allergic and hypersensitivity conditions in the ICD-11 beta phase structure and categorized the conditions as fitting by "precoordination," "postcoordination," "indexed to the ICD-11 Foundation," "no code fit properly" or "no correspondence" in the ICD-11. RESULTS: From overall 125 ICD-10 entities spread in 6 chapters, 57.6% were able to be precoordinated, 4% postcoordinated, 12% indexed to the Foundation, 9.6% had no code fitting properly and 18.6% had no correspondence in the ICD-11 framework. CONCLUSION: We have been able to demonstrate that 83.2% of the ICD-10 allergic and hypersensitivity conditions could be captured by the current ICD-11 beta draft framework. We strongly believe that our findings constitute a key step forward for a softer transition of the ICD-10 allergic and hypersensitivity conditions to the ICD-11, supporting the WHO in this process as well as strengthening the visibility of the Allergy specialty and ensuring quality management of allergic patients.

Left ventricular assist device powered by a balloon counterpulsation console

Mechanical circulatory support system have proven adequate clinical results in patients with severe heart failure, however, most existing devices are only available to few international centers because of high cost.due to the need of ventricular assist devices in Mexico we designed a model to study the factibility of using a conventional counterpulsation console drive module [Program"Mexi-Cor"-mexican heart]. We built a sac type artificial left ventricle, with a non-thrombogenic polyurethane 50cc chamber and two 21 mm prosthetic disc valves [inflow and outflow]. In vitro tests showed adequate driving pressures and at a fixed rate of 80 beats per minute, an output of 4 liters. Experimental animal studies resulted in full hemodynamic support of the excluded left ventricle during 8 hour acute experiments. The device can be placed paracorporeal or implanted in the abdomen in extraperitoneal fashion. Our results demonstrate that counterpulsation consoles can drive ventricular assist device; hence reducing complexity and costs. It is our consideration that these type of devices can represent the future therapy for short term mechanical cardiac support; needing intensive multicenter further research